This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...
Specialty pharma launches depend heavily on data from outside the organization. Distributors, third-party logistics providers ...
Since then, that mindset has continued to grow at AbbVie.
FDA authorization covers adults and children ≥6 years (≥20 kg) for once-daily centanafadine ER, positioned as a CNS stimulant with a first-in-class NDSRI mechanism. Evidence derived from four pivotal ...
Indication includes adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia, for LDL-C ...
EUA marks the first U.S. multiplex PCR capable of differential detection of HSV-1, HSV-2, VZV, and MPXV from a single specimen. Overlapping lesion morphology makes sequential single-pathogen testing ...
Narrow votes supported compounding of BPC-157, KPV, and TB-500 (8-6; one abstention) and MOTS-c (7-5; two abstentions), without constituting FDA approval or demonstrated clinical benefit. Regulatory ...
A stepped tariff schedule targets generics only, preserving existing treatment for patented and innovative drugs while signaling punitive intent for firms that do not invest in U.S. plant and ...
Leavitt Partners' Julie Tierney and RC Resolve, part of Real Chemistry's Maggie Farley, look at which pharma policies could actually pass — and how companies should talk to stakeholders if pricing or ...
In today's Pharmaceutical Executive Daily, FDA converts Fabhalta's accelerated approval to full approval for IgA nephropathy, ...
Litigation targets comparative efficacy messaging that allegedly pits Zepbound 10/15 mg against Wegovy 1.7/2.4 mg while omitting FDA-approved 7.2 mg Wegovy, complicating head-to-head implications.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results